Eloralintide
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Eloralintide
- amy 1176
- AMY-1176
- amy1176
- AMY1176
- eloralintida
- Eloralintida
- eloralintide
- Eloralintide
- ELORALINTIDE [USAN]
- eloralintide usan
- ly 3841136
- LY-3841136
- ly3841136
- Ly3841136
- LY3841136
- CAS registry numbers
- 2883634-40-8
- ChEMBL ID
- CHEMBL6068462
- FDA ingredient codes (UNII)
- 73G3354J8W
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -tide
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Obesity
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Overweight
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005935
- Subject identifier
- D050177
- Condition identifier
- EFO_0000400
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005935
- Condition identifier
- HP_0001513
- Highest recorded phase
- 3
- Condition identifier
- HP_0025502
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005015
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005178
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007147
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 2
- NCT05295940
- NCT06345066
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (21)
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
- A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight
- A Study of Eloralintide (LY3841136) in Healthy Participants
- A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
- A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
- A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
- A Study of LY3841136 in Healthy and Overweight Participants
- A Study of LY3841136 in Japanese Participants With Obesity or Overweight
- A Study of LY3841136 in Overweight and Obese Participants
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
In development for (2)
- Diabetes mellitus Phase 1
- Obesity disorder Phase 1